Journals / Haseki Tıp Bülteni / 2013 / Cilt: 51 - Sayı: 1

A new marker for endothelial function in peritoneal dialysis patients: Apelin

Periton diyalizi hastalarında yeni bir endotel fonksiyonu belirteci: Apelin

Pages
5–10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Apelin may be used as a new marker for ED and a treatment alternative in PD patients. (The Medical Bulletin of Haseki 2013; 51: 5-10)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The most important cause of death in end-stage renal disease is cardiovascular diseases (CVDs).
📊
Key Findings & Data:Results: There was a negative correlation between apelin and FMD percentage (r=-0.334, p=0.03).
💡
Conclusion & Impact:Apelin may be used as a new marker for ED and a treatment alternative in PD patients. (The Medical Bulletin of Haseki 2013; 51: 5-10)
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: The most important cause of death in end-stage renal disease is cardiovascular diseases (CVDs). Endothelial dysfunction (ED) is one of the most important steps in the pathogenesis of CVD. Apelin is a peptide recently found to have important roles in cardiovascular and endothelial physiology; and we planned in our study to examine the relationship between apelin and endothelial functions in peritoneal dialysis (PD) patients. Methods: Forty-two patients who were followed up in the PD unit at Haseki Training and Research Hospital were involved. Endothelial functions were evaluated ultrasonographically by flow-mediated dilation (FMD) test. Apelin levels and routine laboratory tests were studied from the blood samples obtained from the patients. Results: There was a negative correlation between apelin and FMD percentage (r=-0.334, p=0.03). FMD percentage positively correlated with triglyceride and very low density lipoprotein levels (r=0.310, p=0.046; r=0.304, p=0.05, respectively). FMD percentage significantly positively correlated with systolic and diastolic blood pressure (r=0.565,p=<0.001; r=0.560,p=<0.001, respectively). FMD was significantly lower patients with hypertension, compared to those without hypertension (9±5.8 vs. 14.9±6.6; p=0.01). Conclusion: ED is closely related with hypertension and lipid profile in PD patients. Apelin may be used as a new marker for ED and a treatment alternative in PD patients. (The Medical Bulletin of Haseki 2013; 51: 5-10)

Özet

Amaç: Son dönem böbrek yetersizliğinde en önemli mortalite sebebi kardiyovasküler hastalıklardır (KVH). KVH patogenezinde en önemli basamaklardan birisi endotel disfonksiyonudur (ED). Apelin son yıllarda kardiyovasküler sistem ve endotel fizyolojisinde önemli rolleri gösterilmiş bir peptiddir. Çalışmamızda periton diyalizi (PD) hastalarında apelin ile endotel fonksiyonları arasındaki ilişkiyi incelemeyi planladık. Yöntem: Haseki Eğitim ve Araştırma Hastanesi PD Ünitesi’nden takipli 42 hasta çalışmaya alındı. Endotel fonksiyonları ultrasonografikolarak akım aracılı dilatasyon (AAD) yüzdesi ile değerlendirildi. Hastalarda alınan kan örneklerinde rutin biyokimyasal tetkikler ve apelin ölçümü yapıldı. Bulgular: Apelin ile AAD yüzdesi arasında negatif korelasyon saptandı (r=-0.334, p=0.03). AAD yüzdesi ile trigliserid ve çok düşük dansiteli lipoprotein (VLDL) düzeyleri arasında pozitif korelasyon olduğu görüldü (sırasıyla r=0.310, p=0.046; r=0.304, p=0.05). AAD yüzdesi ile sistolik kan basıncı ve diyastolik kan basıncı arasında anlamlı negatif korelasyon mevcuttu (sırasıyla r=0.565, p=<0.001; r=0.560, p=<0.001). Hipertansiyon olan grupta olmayan gruba göre AAD yüzdesi belirgin olarak düşük bulundu (sırasıyla 9.0±5.8 ve 14.9±6.6; p=0.01). Sonuç: ED PD hastalarında hipertansiyon ve lipid profili ile yakın ilişkilidir. Apelin ise PD hastalarında ED açısından yeni bir belirteç ve tedavi alternatifi olarak kullanılabilir. (Haseki Tıp Bülteni 2013; 51: 5-10)

🔖

Cite This Article

KARADAĞ, S., GÜRSU, M., ÖZTÜRK, S., GÜRDAL, A., BASINOĞLU, F., AYDIN, Z., UZUN, S., ŞUMNU, A., ATALAY, E., OFLAZ, H., KAZANCIOĞLU, R. (2013). A new marker for endothelial function in peritoneal dialysis patients: Apelin. Haseki Tıp Bülteni, Cilt: 51 - Sayı: 1, 5–10. https://ajindex.com/articles/268241

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Miller LM, Sood MM, Sood AR, et al. Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients. Int Urol Nephrol 2010;42:1007-14
  2. Tatematsu S, Wakino S, Kanda T, et al. Role of nitric oxide- producing and–degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2007;18:741-9
  3. O'Dowd BF Heiber M, Chan A, et al. A human gene that shows, identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993;136:355-60
  4. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471-6
  5. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF The. apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Arq Bras Cardiol 2008;90:343-9
  6. Japp AG, Newby DE. The apelin-APJ system in heart failure pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008;75:1882-92
  7. Falcao-Pires I, Leite-Moreira AF Apelin: a novel neurohumoral. modulator of the cardiovascular system: pathophysiologic importance and potential use as a therapeutic target. Rev Port Cardiol 2005;24:1263-76
  8. Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001;99:87-92
  9. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001;132:1255-60
  10. Szakodi I, Tavi P Foldes G, et al. Apelin, the novel endogenous, ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002;91:434–40
  11. Taheri S, Murphy K, Cohen M, et al. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 2002;291:1208–12
  12. Malyszko J, Malyszko JS, Kozminski P Mysliwiec M. Apelin and cardiac function in hemodialyzed patients: possible relations? Am J Nephrol 2006;26:121-6
  13. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci 2008;53:32-6
  14. Malyszko J, Malyszko JS, Pawlak K,Wolczynski S,